Physiological Changes During Pregnancy: Cardiac, Respiratory & More

Pregnancy causes a physiological increase in blood volume by approximately 50%, which can dilute red blood cell concentration and appear as anemia on blood tests. This is called dilutional anemia and is not a true iron deficiency. The increased iron requirements during pregnancy are real, but the test results may be misleading. Proper diagnosis requires considering the physiological changes of pregnancy.

Anemia in pregnancy is characterized by impaired hemoglobin synthesis due to iron deficiency, with WHO defining the lower limit as 110 g/L in the first and third trimesters and less than 105 g/L in the second trimester; however, hemodilution is a normal physiological process where plasma volume increases nearly twice as much as red blood cell volume, causing relative reduction in red blood cell concentration without morphological changes, which facilitates placental nutrient and gas exchange. Diagnosis requires distinguishing between these conditions through blood tests including hemoglobin, ferritin, and transferrin levels, with treatment involving iron supplementation and dietary management.

Pregnancy induces profound hemodynamic and metabolic changes to support maternal-fetal physiology. Blood volume expands 40-50% with plasma increasing more than RBC mass, creating protective hemodilution that buffers against blood loss during delivery and prevents excessive clotting. Water retention totals 6.5 liters, with mechanisms including decreased thirst threshold and direct renal effects. Sodium and potassium retention occurs but serum concentrations remain normal due to concurrent water retention. Hemodilution affects lab interpretation—for example, sickle cell trait carriers may be asymptomatic after blood loss during pregnancy. Blood pressure naturally decreases with diastolic pressure falling more than systolic. Supine hypotension syndrome occurs when the uterus compresses the inferior vena cava, relieved by left lateral positioning. Edema results from hemodilution, decreased peripheral resistance, and hypoalbuminemia—typically pitting and dependent. Physiological anemia occurs as hemoglobin decreases from 12g/dL to 10g/dL at 32 weeks due to hemodilution despite increased RBC mass. Total iron requirement is 1000mg, distributed unevenly (3-4mg/day first half, 6-7mg/day second half). Iron supplementation should begin in the second trimester when gastrointestinal tolerance is better. Diagnostic thresholds for anemia are lower in pregnancy (Hb<11g/dL, Hct<33%). Serum iron decreases while total iron binding capacity increases. MCV is slightly elevated due to younger, larger red blood cells.

Physiological anemia during pregnancy occurs because plasma volume increases more (40-50%) than RBC mass (20-30%). This disproportionate increase in plasma volume dilutes the blood, resulting in lower hematocrit and hemoglobin concentration despite actual increases in total hemoglobin and RBC mass. Hemodilution provides several benefits: reduced blood viscosity improves blood flow and facilitates gas exchange for both mother and fetus, increased blood volume helps maintain blood pressure during supine position (preventing supine hypotensive syndrome), and provides adequate blood supply for placental perfusion and fetal development.

Physiological anemia of pregnancy results from hemodilution (increased plasma volume) and increased iron demands, causing relative hemoglobin reduction without true pathology. Normal hemoglobin drops from 14.8 g/dL to 11-14 g/dL in second trimester. Thalassemia presents similarly as microcytic hypochromic anemia but requires differentiation from iron deficiency through MCH (<27 pg) and hemoglobin electrophoresis. Beta thalassemia major causes severe congenital hemolytic anemia requiring lifelong transfusions. Understanding this distinction prevents inappropriate iron supplementation in thalassemia.

Pregnancy induces significant pharmacokinetic changes including decreased serum albumin leading to increased volume of distribution for highly protein-bound drugs, increased hepatic blood flow and cytochrome P450 enzyme activity (particularly CYP3A4, CYP2D6, and CYP1A2) which increases drug clearance, and increased glomerular filtration rate by up to 50% affecting renal elimination; however, adherence remains the most critical variable in drug therapy during pregnancy, as many women discontinue necessary medications due to fear of teratogenic effects, and physicians must individualize dosing based on these physiological changes while communicating potential dose adjustments throughout pregnancy.

Pregnancy significantly alters drug pharmacokinetics: (1) Absorption changes include reduced gastric acid secretion, delayed gastric emptying, increased intestinal blood flow, and increased intestinal motility; (2) Distribution changes include increased total body water, increased plasma volume, decreased albumin levels, and increased fat mass; (3) Metabolism changes include increased hepatic blood flow, increased CYP3A4 activity, and increased glucuronidation; (4) Excretion changes include increased GFR (50% increase in first trimester, 100% by third trimester) and increased tubular secretion. These changes may require dose adjustments.

Pregnancy causes significant pharmacokinetic changes: gastric emptying slows (increased progesterone), gastric pH increases, plasma volume expands, albumin decreases, and alpha-1 acid glycoprotein decreases. These changes increase free drug fractions and alter absorption. Renal blood flow and glomerular filtration rate increase 25-50%, increasing drug elimination. Lopinavir/ritonavir concentrations decrease and may need adjustment in 2nd/3rd trimesters.

Pregnancy significantly alters drug pharmacokinetics through absorption, distribution, metabolism, and elimination. Absorption of enteral drugs may be impaired by gastric upset and vomiting, while inhalational agents absorb more rapidly due to increased minute ventilation. Distribution changes include increased blood volume, decreased plasma protein (especially albumin), and altered pH levels. Metabolism and elimination are enhanced by 30-50% increase in glomerular filtration rate. These changes affect drug dosing requirements and therapeutic outcomes in pregnant patients.

Pregnancy significantly alters drug pharmacokinetics: (1) Absorption is delayed due to reduced gastric motility, (2) Distribution volume increases due to increased body fat and decreased albumin levels, (3) Metabolism may be altered, and (4) Excretion increases due to elevated glomerular filtration rate. These changes result in lower peak drug concentrations and faster elimination, requiring dose adjustments (often lower doses with more frequent administration) to maintain therapeutic efficacy.

Postpartum hypercoagulability increases thromboembolic risk including superficial thrombophlebitis, deep vein thrombosis (risking pulmonary embolism), and venous stasis. Prevention includes TED hose, leg exercises, and anticoagulant therapy for high-risk patients. Amniotic fluid embolism, though rare, causes immediate cardio-pulmonary collapse when amniotic fluid enters maternal circulation. Risk factors include advanced maternal age, multiple gestation, placenta previa, oxytocin administration, and forceps-assisted birth. Emergency management requires immediate CPR and emergency cesarean section within 3-4 minutes to remove the stressor and improve neonatal survival.

This segment covers recognition and management of thromboembolic emergencies. For DVT: presents with leg pain, swelling, and tenderness. For Pulmonary Embolism: presents with sudden chest pain, dyspnea, and hypoxia. For Amniotic Fluid Embolism: presents with sudden collapse during or after delivery, hypotension, shock, and DIC. Management priorities: (1) High-flow oxygen administration first. (2) Anticoagulation with heparin (warfarin is contraindicated during lactation). (3) Thrombolysis or embolectomy for severe cases. For Amniotic Fluid Embolism specifically: (1) Code Blue activation is required. (2) High-flow oxygen, intubation, IV fluids, vasopressors, and correction of coagulopathy with fresh frozen plasma and platelets. (3) This is the most severe obstetric emergency requiring immediate multidisciplinary intervention.

This video demonstrates the comprehensive management of amniotic fluid embolism in obstetric critical care, including immediate ACLS response with chest compressions at 30:2 ratio, epinephrine administration, and Massive Transfusion Protocol activation; cesarean delivery is performed after four minutes of unsuccessful resuscitation using a vertical incision to facilitate rapid fetal extraction while continuing maternal resuscitation efforts, with post-resuscitation care focusing on hemodynamic optimization and ICU transfer.

Amniotic fluid embolism is one of the most dangerous obstetric emergencies, causing rapid cardiovascular collapse. Dr. Lyn predicted amniotic fluid embolism within 10 minutes for a 33-week pregnant patient with severe hypertension and irregular contractions. The condition causes respiratory, circulatory, and blood function collapse, with death potentially occurring within six minutes. She coordinated with anesthesia, blood bank, and newborn units, administering medications for allergy treatment, pulmonary artery spasm prevention, and DIC management. This demonstrates that obstetric emergencies require: (1) rapid recognition of warning signs, (2) immediate intervention, and (3) multidisciplinary team coordination.

Amniotic Fluid Embolism (AFE) is a rare but life-threatening obstetric emergency characterized by the classic triad of hypotension, hypoxia, and coagulopathy, which has been reclassified from a mechanical pulmonary embolism to an anaphylactoid/septic shock-like syndrome caused by fetal antigens entering maternal circulation and triggering systemic inflammatory mediator activation; management requires aggressive supportive care including vasopressors, inotropes, and consideration of extracorporeal life support, with mortality rates of 70-80%, and clinicians must quickly distinguish it from other causes of shock such as pulmonary thromboembolism, transfusion reactions, and bleeding to avoid inappropriate anticoagulation.